Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135809 | 0.89 | POLB (0.54) | MAPTPOLBLMNARIPK1ROCK1 | |
| SCHEMBL2821445 | 0.89 | RIPK1 (0.48) | RIPK1KMT2AMEN1CSF1RFLT4 | |
| SCHEMBL12973391 | 0.84 | MAPT (0.50) | MAPTPOLBLMNAROCK1PRKACA | |
| SCHEMBL2816530 | 0.84 | MAPT (0.50) | MAPTPOLBLMNAROCK1PRKACA | |
| SCHEMBL2816038 | 0.82 | LMNA (0.46) | LMNAKMT2AMEN1CSF1RKIT | |
| SCHEMBL13135799 | 0.79 | KDM4E (0.43) | MAPTPOLBLMNAKMT2ACYP2C19 | |
| SCHEMBL2817355 | 0.76 | FLT3 (0.49) | MAPTRIPK1ROCK1KMT2AMEN1 | |
| SCHEMBL2816625 | 0.75 | KDR (0.73) | RIPK1ROCK1CSF1RFLT4FLT3 | |
| SCHEMBL12973193 | 0.75 | CSF1R (0.42) | MAPTLMNAKMT2AMEN1CYP3A4 | |
| SCHEMBL2819422 | 0.74 | NPC1 (0.46) | MAPTKMT2AMEN1CSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | claimed |
| EP-2032573-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-11 | — | — | EP | claimed |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | claimed |
| WO-2007144203-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | claimed |
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | disclosed |
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | disclosed |
| US-7795264-B2 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1870410-A1 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870410-A1 | Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144203-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144204-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | MAPT 3460/4885POLB 3462/4885LMNA 3934/4885 |
| US-20080064707-A1 | SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, TEK | MAPT 3699/4885POLB 3838/4885LMNA 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.